<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02767310</url>
  </required_header>
  <id_info>
    <org_study_id>ROS/2016/1278</org_study_id>
    <nct_id>NCT02767310</nct_id>
  </id_info>
  <brief_title>Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)</brief_title>
  <official_title>A Pivotal, Open-label, Balanced, Randomised, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Single Oral Dose Bioequivalence Study of Rosuvastatin/ Verisfield 20 mg Film-coated Tablets Versus Crestor/ AstraZeneca 20 mg Film-coated Tablets in Healthy Adults Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Verisfield UK Ltd. Greek Branch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Verisfield UK Ltd. Greek Branch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the bioequivalence of Rosuvastatin/ Verisfield 20&#xD;
      mg film-coated tablets and Crestor™/ AstraZeneca 20 mg film-coated tablets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to compare the absorption and disposition kinetics of two products containing&#xD;
      rosuvastatin under fasting conditions. These products are: Rosuvastatin/ Verisfield 20 mg&#xD;
      film-coated tablets, a Test product manufactured by HELP S.A., Greece and Crestor™/&#xD;
      AstraZeneca 20 mg film-coated tablets, a Reference product manufactured by AstraZeneca, UK.&#xD;
      The bioequivalence of a single 20 mg dose of both products will be assessed by comparing the&#xD;
      pharmacokinetic parameters derived from the plasma concentration-time profiles for&#xD;
      rosuvastatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration (AUC0-t) from zero (0) hours to time (t)</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>The area under the plasma concentration versus time curve, from time zero (0) to t hours</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>Maximum measured plasma concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to maximum concentration (Tmax)</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>Time of the maximum measured plasma concentration. If the maximum value occurs at more than one time point, tmax is defined as the first time point with this value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination rate constant (Kel)</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>Apparent first-order elimination or terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half life (t1/2)</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>The elimination or terminal half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration (AUC0-infinity) from zero (0) hours to infinity</measure>
    <time_frame>Before dosing (0 hour) and 0.25, 0.50, 0.75, 1.50, 2.00, 2.50, 3.00, 3.50, 4.00, 4.50, 5.00, 6.00, 7.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00 and 48.00 hours post-dose</time_frame>
    <description>The area under the plasma concentration versus time curve from time (0) to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Test Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg film-coated tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Crestor 20 mg film-coated tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg film-coated tablets</intervention_name>
    <description>Single oral dose of 20 mg</description>
    <arm_group_label>Test Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Crestor 20 mg film-coated tablets</intervention_name>
    <description>Single oral dose of 20 mg</description>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Willingness to provide informed consent to participate in the study.&#xD;
&#xD;
          -  Comprehension of the nature and purpose of the study and willingness to comply with&#xD;
             the requirements of the entire procedure.&#xD;
&#xD;
          -  Healthy adult, human Indian volunteers within the age range of 18 to 45 years (both&#xD;
             inclusive).&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 18.50 kg/m2 to ≤ 30.00 kg/m2.&#xD;
&#xD;
          -  Hemoglobin: ≥12.0 gm% for male and ≥11.5 gm% for female.&#xD;
&#xD;
          -  Absence of disease markers of HIV I &amp; II, HBsAg, HCVAb and P24 antigen test.&#xD;
&#xD;
          -  Females of childbearing age must be practicing an acceptable form of birth control for&#xD;
             at least six months before screening, unless they have had bilateral oophorectomy or&#xD;
             tubal ligation or their male partner has had vasectomy.&#xD;
&#xD;
          -  Females of childbearing age agree to use acceptable form of birth control during the&#xD;
             study and until the drug is washed out from the body, i.e. at least 14 days after last&#xD;
             dosing, unless they have had bilateral oophorectomy or tubal ligation or their male&#xD;
             partner has had vasectomy.&#xD;
&#xD;
          -  Absence of significant disease or clinically significant abnormal laboratory values&#xD;
             during the laboratory evaluations.&#xD;
&#xD;
          -  Absence of any diseases in medical history or physical examination during the&#xD;
             screening.&#xD;
&#xD;
          -  Have a normal 12-lead ECG or one with abnormality considered clinically insignificant.&#xD;
&#xD;
          -  Have a normal chest X-ray (P. A. view).&#xD;
&#xD;
          -  Non smokers (since last six months)&#xD;
&#xD;
          -  Negative serum β-HCG at the time of screening (for females only)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History / evidence of allergy or hypersensitivity to rosuvastatin or to any of the&#xD;
             excipients or to any other drug.&#xD;
&#xD;
          -  Any major illness within the last three months or any significant ongoing chronic&#xD;
             medical illness.&#xD;
&#xD;
          -  History of or active liver or kidney disease.&#xD;
&#xD;
          -  History of or active deep vein thrombosis and thromboembolic disorders.&#xD;
&#xD;
          -  History of breast cancer, endometrial cancer or other estrogen-dependent neoplasia,&#xD;
             endometriosis and undiagnosed vaginal bleeding (for females only).&#xD;
&#xD;
          -  History of drug abuse (including barbiturates, benzodiazepines, opioids, cocaine,&#xD;
             cannabinoids and amphetamine etc.) within the last three months.&#xD;
&#xD;
          -  History of neuropsychiatric diseases.&#xD;
&#xD;
          -  History of hypothyroidism.&#xD;
&#xD;
          -  Personal or family history of hereditary muscular disorders.&#xD;
&#xD;
          -  History of myopathy.&#xD;
&#xD;
          -  History of myalgia.&#xD;
&#xD;
          -  History of rhabdomyolysis.&#xD;
&#xD;
          -  History of alcohol abuse.&#xD;
&#xD;
          -  History of proteinuria.&#xD;
&#xD;
          -  Asian population (except Indian).&#xD;
&#xD;
          -  History of interstitial lung disease.&#xD;
&#xD;
          -  History of or current gastro-intestinal diseases influencing drug absorption.&#xD;
&#xD;
          -  History of alcoholism (more than two years), moderate drinkers (more than three drinks&#xD;
             per day).&#xD;
&#xD;
          -  Participation in any clinical trial within last three months.&#xD;
&#xD;
          -  History of difficulty with donating blood or difficulty in accessibility of veins in&#xD;
             left or right arm.&#xD;
&#xD;
          -  Donation of blood (one unit or 350 mL or more) within last three months.&#xD;
&#xD;
          -  Use of any prescription drug therapy within last two weeks and over the counter (OTC)&#xD;
             drugs or herbal products within last one week.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Breast feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathiria Jayesh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Synchron Research Services Pvt. Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Synchron Research Services Pvt. Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380056</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <last_update_submitted>July 4, 2016</last_update_submitted>
  <last_update_submitted_qc>July 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bioequivalence</keyword>
  <keyword>two rosuvastatin-containing products</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

